Leading drug discovery tools provider continues to strengthen patent protection for Transcreener HTS Assay Platform.
Madison, WI – May 27, 2008 – BellBrook Labs, a leading provider of high throughput screening tools for the drug discovery industry, today announced that the U.S. Patent and Trademark Office has approved the issuance of two patents (U.S. Pat. No. 7,355,010 and 7,378,505) to BellBrook Labs for the Transcreener™ HTS Assay platform. These are the second and third patents to issue in a series of allowed patents covering the Transcreener technology.
“No other technology platform allows screening of so many targets, both well characterized and emerging, as Transcreener” stated Bob Lowery, CEO of BellBrook Labs. “The strength of the technology has resulted in widespread adoption in large-scale compound screens among the top pharmaceutical and biotechnology companies around the world.”
Transcreener is a universal, high throughput biochemical assay based on detection of nucleotides, including ADP, UDP, AMP and GMP, which are formed by thousands of cellular enzymes. Among these are enzyme families, such as kinases, ATPases, ligases, synthetases, carboxylases, phosphodiesterases, and glycosyltransferases, which catalyze the covalent regulatory reactions that are central to cell signaling and are high value targets in drug discovery.
The first three patents to issue cover the method, limited to group transferase enzymes that produce ADP and the antibody and tracer used to detect ADP producing enzymes. Additional patent applications pertaining to the Transcreener technology have been filed by Quarles & Brady on BellBrook’s behalf.
About BellBrook Labs
Founded in 2002, BellBrook Labs provides the pharmaceutical industry with high throughput screening (HTS) tools that accelerate the discovery of effective therapies. In 2005, with the development of the Transcreener Assay Platform, BellBrook Labs introduced HTS methods that removed the assay development bottlenecks restricting access to many promising therapeutic, ADME and safety drug targets. Data generated from these assays allows better prediction about how patients will respond to drugs and improves the business case for drug target testing and the development of new drug treatments. BellBrook Labs acquired Salus Technologies in 2007 to develop a novel technology platform that enables screening labs to expand their cellular assay capabilities. By providing innovative biochemistry and cell biology technologies, BellBrook is able to answer many of the challenges faced by drug discovery.
Biology at Work